TheEdgeResearch
Home / Stocks / GNRSW

Greenrose Acquisition Corp. (GNRSW)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.00 ▼ -99.67%
Market Cap
$1,768
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
3309.14
52-Wk Range
1.0E-6-1.0E-6
CEO
Nicole Conboy
Country
US
Currency
USD

Greenrose Acquisition Corp. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in DE, US. The stock last traded at $0.00, down 99.67% on the session, giving a market capitalisation of $1,768. On trailing twelve-month figures it carries a trailing P/E of 0.00, a net margin of 70.6%. Its beta of 3309.14 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
0.00
Price / Sales
0.00
Price / Book
0.00
EV / EBITDA
4.51
Gross margin
59.1%
Operating margin
38.7%
Net margin
70.6%
Return on equity
Debt / equity
1.57
Current ratio
0.21
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
91
IPO date
2020-05-11
Headquarters
DE, US
About Greenrose Acquisition Corp.

Greenrose Holding Company Inc., operating via its subsidiaries, specializes in the manufacturing and commercialization of cannabis products. Its core business functions include cultivating, processing, and packaging medicinal cannabis and its related derivative items. The organization was established in 2014 and maintains its corporate headquarters in Amityville, New York.

Comparable companies

Greenrose Acquisition Corp. is most often compared with the following Healthcare names:

BLEVFEPRSQGWHPINTPMLTOORVRFRXEISEYEWLNSFXCRP
More research on GNRSW
GNRSW technical analysis GNRSW TheEdge Score Compare against peers
Open full interactive analysis & DCF →